About Us


The company owns therapeutic compounds for inflammatory diseases, with molecules having achieved extensive phase 3 results in the field of eye and ear inflammation.

Our vision

KUSTE BIOPHARMA expands the use of these molecules to inflammatory urological diseases whose medical needs are currently unmet, such as Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS).
Existing clinical data also support other possible developments, for example on Inflammatory Bowel Disease (IBD).

KUSTE BIOPHARMA has closed a relevant financial round to launch Phase 2 clinical studies on IC/PBS and preclinical studies on other applications.

& Partnerships

Kuste Biopharma

2 bis rue Tête d’Or
69006 Lyon

5 rue de Castiglione
75001 Paris

+33 (0) 481 133 530

Retour haut de page